Ads
related to: sickle cell disease
Search results
Results From The WOW.Com Content Network
(Reuters) -U.S. drugmaker Pfizer said on Wednesday it is withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks of a painful complication and deaths.
Sickle cell disease affects an estimated 100,000 people in the U.S., most of whom are Black. The withdrawal is the latest headwind for Pfizer and its CEO Albert Bourla. Investors have punished the ...
Sickle cell disease (SCD), also simply called sickle cell, is a group of hemoglobin-related blood disorders typically inherited. [2] The most common type is known as sickle cell anemia. [2] It results in an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. [2] This leads to a rigid, sickle -like shape under ...
The types of anemia treated with drugs are iron-deficiency anemia, thalassemia, aplastic anemia, hemolytic anemia, sickle cell anemia, and pernicious anemia, the most important of them being deficiency and sickle cell anemia with together 60% of market share because of highest prevalence as well as higher treatment costs compared with other ...
1 in 10,000 people [2] Spinal muscular atrophy (SMA) is a rare neuromuscular disorder that results in the loss of motor neurons and progressive muscle wasting. [3][4][5] It is usually diagnosed in infancy or early childhood and if left untreated it is the most common genetic cause of infant death. [6] It may also appear later in life and then ...
CEO Andrew Obenshain said the latest restructuring would help support the marketing of its three gene therapies, including the recently approved sickle cell disease treatment, Lyfgenia.